A Phase II Trial of Paclitaxel Administered Weekly in Patients With Advanced Ovarian Cancer
OBJECTIVES: I. Evaluate the activity of paclitaxel when administered on a weekly schedule to
patients with advanced ovarian cancer who have failed paclitaxel on a 3 or 24 hour infusion
schedule. II. Evaluate the toxic effects of paclitaxel when administered on a weekly
schedule in this patient population. III. Correlate response with quality of life outcomes,
including symptom distress, performance status, and global quality of life.
OUTLINE: This is a single center, open label study. Paclitaxel is administered intravenously
every week as a 1 hour infusion. Patients receive prophylactic anti-allergy premedication
prior to paclitaxel.
PROJECTED ACCRUAL: 25-30 patients accrued per year.
Primary Purpose: Treatment
Carol Aghajanian, MD
Memorial Sloan-Kettering Cancer Center
United States: Federal Government
|Memorial Sloan-Kettering Cancer Center||New York, New York 10021|